China Cord Blood Corporation (CO) - NYSE
  • Wed, Jun. 15, 6:20 AM
    • China Cord Blood (CO) FQ4 results: Revenues: 156.8M (-3.8%); Operating Expense: 82.5M (+4.4%); Operating Income: 39.7M (-19.8%); Net Income: 8.2M (-51.5%); EPS: 0.18 (-21.7%); CF Ops: 138.9M (-5.1%).
    • FY2016 results: Revenues: 663M (+4.4%); Operating Expense: 327.1M (+21.4%); Operating Income: 191.3M (-18.6%); Net Income: 91M (-15.2%); EPS: 1.25 (-8.1%); Quick Assets: 3008.4M (+23.5%); CF Ops: 581M (-2.3%).
    • No guidance given.
    | Wed, Jun. 15, 6:20 AM
  • Tue, Jun. 14, 4:18 PM
    • China Cord Blood (NYSE:CO): FQ4 EPS of $0.03 in-line.
    • Revenue of $24.3M (-7.6% Y/Y) misses by $1.57M.
    • Press Release
    | Tue, Jun. 14, 4:18 PM
  • Mon, Feb. 29, 4:27 PM
    • China Cord Blood (NYSE:CO): Q4 EPS of $0.10 beats by $0.05.
    • Revenue of $26.15M (-2.6% Y/Y) misses by $0.85M.
    • Press Release
    | Mon, Feb. 29, 4:27 PM
  • Nov. 24, 2015, 7:50 AM
    • China Cord Blood (CO +0.8%) FQ2 results (NYSEARCA:RMB): Revenues: 171.5M (+12.8%); R&D Expense: 2.2M (-4.3%); SG&A: 79.6M (+28.4%); Operating Income: 52.5M (-8.7%); Net Income: 18.7M (-31.3%); EPS: 0.25 (-28.6%); Quick Assets: 2,436.7M (-8.8%).
    • No guidance given.
    | Nov. 24, 2015, 7:50 AM
  • Nov. 23, 2015, 4:21 PM
    • China Cord Blood (NYSE:CO): FQ2 EPS of $0.04 in-line.
    • Revenue of $26.98M (+8.9% Y/Y) beats by $0.56M.
    | Nov. 23, 2015, 4:21 PM
  • Aug. 20, 2015, 8:00 AM
    • China Cord Blood (CO -2.1%) FQ1 results (NYSEARCA:RMB): Revenues: 165.4M (+7.9%); Gross Profit: 128.8M (+4.2%); Operating Expenses: 80.4M (+26.8%); Operating Income: 48.4M (-19.6%); Net Income: 13.6M (-54.2%); EPS: 0.19 (-48.6%); Quick Assets: 2,560.9M (+5.1%); CF Ops: 130.1M (+4.4%).
    • No guidance given.
    | Aug. 20, 2015, 8:00 AM
  • Aug. 19, 2015, 4:06 PM
    • China Cord Blood (NYSE:CO): FQ1 EPS of $0.03 misses by $0.01.
    • Revenue of $26.7M (+8.0% Y/Y) beats by $0.89M.
    | Aug. 19, 2015, 4:06 PM | 1 Comment
  • Aug. 6, 2015, 9:15 AM
    | Aug. 6, 2015, 9:15 AM | 9 Comments
  • Aug. 6, 2015, 8:27 AM
    • Thinly traded micro cap China Cord Blood (NYSE:CO) is up 26% premarket on increased volume in response to its announcement that it received a non-binding acquisition proposal letter from Nanjing Xinjiekou Department Store Co., Ltd. offering to buy the firm at a price no lower than RMB6.0B ($960M), to be paid in cash or a combination of cash and stock.
    • The special committee of the company's board of directors will carefully assess the proposal.
    | Aug. 6, 2015, 8:27 AM | 4 Comments
  • Jul. 6, 2015, 1:11 PM
    • Thinly traded small cap China Cord Blood (CO -15.2%) is down on double normal volume, albeit on turnover of only 612K shares. No particular news accounts for the move. Management has been mulling a bid for the company by Golden Meditech Holdings.
    | Jul. 6, 2015, 1:11 PM | 2 Comments
  • Jul. 6, 2015, 12:49 PM
    | Jul. 6, 2015, 12:49 PM | 2 Comments
  • Jul. 2, 2015, 9:07 AM
    • Onconova (NASDAQ:ONTX) upgraded to Overweight from Neutral with a $6 (131% upside) price target (up from $3) by Piper Jaffray.
    • BioCryst Pharmaceuticals (NASDAQ:BCRX) upgraded to Buy from Neutral with a $19 (30% upside) price target (up from $12) by Bank of America.
    • Kythera Biopharmaceuticals (NASDAQ:KYTH) downgraded to Market Perform from Outperform with a $65 (13% downside risk) price target (up from $61) by Leerink Swann.
    • Zoetis (NYSE:ZTS) downgraded to Market Perform from Outperform with a $57 (18% upside) price target (up from $51) by BMO.
    • China Cord Blood (NYSE:CO) downgraded to Neutral from Buy with a $6.75 (9% upside) price target (up from $6.50) by Roth Capital.
    • Teladoc (Pending:TDOC) initiated with Outperform rating and $35 (23% upside) price target by RBC.
    • Aldeyra (NASDAQ:ALDX) initiated with Buy rating and $16 (93% upside) price target by Canaccord Genuity.
    • Novagen (NASDAQ:NVGN) initiated with Buy rating and $8.50 (89% upside) price target by H.C. Wainwright.
    | Jul. 2, 2015, 9:07 AM | 10 Comments
  • Jun. 18, 2015, 4:45 PM
    • China Cord Blood (NYSE:CO) fiscal Q4 results ($M): Revenues: 26.3 (+7.3%); Operating Income: 8.0 (-22.7%); Net Income: 2.7 (-57.2%); CF Ops: 23.6 (+6.6%).
    • New subscribers: 15,982; Accumulated subscriber base: 441,359.
    • The company will host its conference call tomorrow morning at 8:00 am ET.
    • Shares are up 3% after hours on light volume.
    | Jun. 18, 2015, 4:45 PM
  • Jun. 18, 2015, 4:03 PM
    • China Cord Blood (NYSE:CO): FQ4 EPS of $0.04 misses by $0.01.
    • Revenue of $26.3M (+7.6% Y/Y) beats by $0.42M.
    | Jun. 18, 2015, 4:03 PM
  • Jun. 17, 2015, 1:30 PM
    • China Cord Blood (CO +5.3%) breaks out of consolidation on a 5x surge in volume. No particular news accounts for the move other than tomorrow's earnings announcement after the close. Consensus views for fiscal Q4 and fiscal 2015 are EPS of $0.05 (-28.6%) and $0.24 on revenues of $25.9M (+6.1%) and $103.3M, respectively.
    • The conference call will start at 8:00 am ET on Friday, June 19.
    | Jun. 17, 2015, 1:30 PM
  • Apr. 27, 2015, 9:16 AM
    • China Cord Blood (NYSE:CO) receives a non-binding proposal letter from current shareholder Golden Meditech Holdings proposing that it acquire all the outstanding stock of the company that it does not already own plus the 7% senior convertible notes. Meditech will finance the transaction with a combination of cash, debt and equity.
    • China Cord's BOD will form a special committee to consider the proposal.
    • Shares are off 8% premarket on light volume.
    | Apr. 27, 2015, 9:16 AM | 1 Comment
Company Description
China Cord Blood Corp. engages in the provision of cord blood banking services. It provides cord blood processing and storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies such as cord blood transplants.... More
Sector: Healthcare
Industry: Medical Laboratories & Research
Country: United States